108 related articles for article (PubMed ID: 27841155)
1. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
.
Schultze-Mosgau MH; Schuett B; Hafner FT; Zollmann F; Kaiser A; Hoechel J; Rohde B
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):16-24. PubMed ID: 27841155
[TBL] [Abstract][Full Text] [Related]
2. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.
Schultze-Mosgau MH; Matsuki S; Okumura K; Kaneko M
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):49-56. PubMed ID: 34635989
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.
Liu H; Jiang J; Chen Z; Zhang Y; Li J; Hoechel J; Rohde B; Zimmermann T; Schultze-Mosgau MH
Clin Pharmacol Drug Dev; 2021 May; 10(5):486-493. PubMed ID: 32716091
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
5. Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women.
Schütt B; Schultze-Mosgau MH; Draeger C; Chang X; Löwen S; Kaiser A; Rohde B
J Clin Pharmacol; 2018 Feb; 58(2):228-239. PubMed ID: 28940451
[TBL] [Abstract][Full Text] [Related]
6. Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women.
Schultze-Mosgau MH; Kaiser A; Zollmann FS
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):675-680. PubMed ID: 33021044
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.
Schultze-Mosgau MH; Lasseter KC; Marbury T; Loewen S; Riecke K
J Clin Pharmacol; 2020 Aug; 60(8):1030-1038. PubMed ID: 32227643
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Schultze-Mosgau MH; Höchel J; Prien O; Zimmermann T; Brooks A; Bush J; Rottmann A
Clin Pharmacokinet; 2018 Aug; 57(8):1001-1015. PubMed ID: 29330782
[TBL] [Abstract][Full Text] [Related]
9. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
11. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
13. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women.
Cristina Castelli M; Bhaskar S; Lippman J
Clin Ther; 2013 Jun; 35(6):862-9. PubMed ID: 23795577
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.
Schultze-Mosgau MH; Ploeger BA; Frei M; Höchel J; Rottmann A
Clin Pharmacokinet; 2022 Jan; 61(1):1-16. PubMed ID: 34569009
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]